WS #12115
J&J beat Q2 estimates and raised guidance, but shares fell on MedTech concerns and Stelara losses.
Johnson & Johnson Q2 Results
J&J beat Q2 estimates and raised guidance, but shares fell on MedTech concerns and Stelara losses.
J&J beat Q2 estimates and raised guidance, but shares fell on MedTech concerns and Stelara losses.
J&J beat Q2 estimates and raised guidance, but shares fell on MedTech concerns and Stelara losses.